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S U M M A R Y
Mycobacterium sherrisii is an acid fast organism that is recently validated as a novel species. It is
recognized to cause severe disease in immunosuppressed individuals especially in patients with HIV. We
describe a case M. sherrisii pneumonia which was diagnosed using PCR coupled with electrospray
ionization mass-spectrometry (PCR/ESI-MS) technology.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Mycobacterium sherrisii is a slow-growing acid-fast organism
that is phylogenetically related to Mycobacterium simiae. It was
only recently validated as a novel species, in 2011.1 Deﬁnitive
identiﬁcation requires a gene sequencing method targeting the
16S–23S rRNA internal transcribed spacer region (ITS), 16S rRNA,
65-kDa heat shock protein (hsp65), or genomic DNA hybridiza-
tion.2 Only a few cases have been reported worldwide, with most
case reports from Africa or with an epidemiological link to an
African country.2–6 Almost all of the reported cases have involved
HIV-infected adults with a CD4 count <100 cells/ml who presented
with either a disseminated infection2–4 or pulmonary infection.5,6
2. Case report
We report the case of a 46-year-old man from Africa who had lived
in Hong Kong for 1 year. He had enjoyed good health in the past, but
reporteda2-weekhistoryofproductivecough,blood-stainedsputum,
subjective weight loss, and low grade fever. Physical examination
was normal, except for multiple cervical lymph nodes and enlarged* Corresponding author. Tel.: +852 2958 2790; fax: +852 2771 7965.
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license (http://creativecommons.org/licenses/by-nc-nd/3.0/).tonsils. A chest X-ray (CXR) (Figure 1A) revealed left upper lobe
consolidation with cavitations, and multiple small lung nodules over
bilateral lung ﬁelds with prominent mediastinal lymph nodes.
Two sputum specimens were saved; the second specimen
revealed acid-fast bacilli by Ziehl–Neelsen stain. PCR for M.
tuberculosis performed by GeneXpert MTB/RIF assay (Cepheid,
Sunnyvale, CA, USA) was negative for M. tuberculosis complex.
The standard doses of isoniazid, rifampin, pyrazinamide, and
ethambutol were started for M. tuberculosis, as it is endemic in Hong
Kong. Azithromycin was added for coverage of non-tuberculous
Mycobacterium (NTM) infections. The patient was also diagnosed
to have an HIV-1 infection, with a CD4 count of 144 cells/ml and viral
load of 868 586 IU/ml. He was discharged 6 days after admission as
he was afebrile, with no hemoptysis and was gaining weight.
At the 4-week follow-up, highly active antiretroviral therapy
(HAART) with ritonavir-boosted atazanavir, abacavir, and lamivu-
dine was started. Rifampin was switched to rifabutin to avoid drug
interaction. A CXR showed partial resolution of the consolidation
(Figure 1B). He remained afebrile, but there was occasional
hemoptysis.
Two sputum specimens subsequently grew M. sherrisii, and
treatment was modiﬁed to ethambutol, azithromycin, rifabutin,
and moxiﬂoxacin. According to previous reports, clarithromycin
may also be regarded as a drug of choice, while ethambutol often
shows high minimum inhibitory concentration (MIC) levels not
reached at therapeutic doses.7ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Figure 1. Mycobacterium sherrisii pneumonia – chest X-ray sequence for the reported case: (A) at presentation; (B) at 4 weeks after initial treatment; (C) at 1 year after
treatment. Note the left upper lobe consolidation with cavitations showed gradual improvement and complete resolution after 1 year of treatment.
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There was complete resolution of symptoms and the CXR cleared
(Figure 1C). He also tolerated HAART and showed a CD4 count of
363 cell/ml and suppressed HIV viral load.
3. Results and discussion
3.1. Mycobacterial culture
The sputa showed photochromogenic growth in Lowenstein–
Jensen medium after 24 days of incubation and growth in the Bactec
Mycobacteria Growth Indicator Tube (MGIT; Becton Dickson
Diagnostic Systems, Sparks, MD, USA) after 6 days 15 h of incubation.
3.2. 16s rRNA and hsp65 analysis
Deﬁnitive identiﬁcation was attempted: 16S sequencing of the
gene spanning 1.5 kb was performed.8 Comparison of the sequenceby ribosomal differentiation of microorganisms (RIDOM) showed
high sequence analogy with Mycobacterium interjectum (99.07%)
and by GenBank with M. sherrisii (100%). PCR-restriction fragment
length polymorphism analysis using restriction fragments pro-
duced by Sau96I and CFol of the hsp65 gene, identiﬁed M. simiae or
Mycobacterium habana.9 The INNO-LiPA reverse-line blot assay
(Hian Life Science) identiﬁed M. simiae.
3.3. PCR coupled with electrospray ionization mass-spectrometry
(PCR/ESI-MS)
The isolate was sent for further characterization by PCR/ESI-MS,
not yet approved for clinical diagnostics.10 Two distinct PCR/ESI-
MS assays were used. The ﬁrst was a broad bacterial assay
providing broad-range bacterial detection. Mycobacterial species
are identiﬁed by database matching using a subset of eight primer
pairs (4235, 4236, 4237, 4364, 3828, 3697, 3555, and 4364) that
C. Lai et al. / International Journal of Infectious Diseases 25 (2014) 119–121 121are the most informative for species characterization. Compara-
tively long amplicons are yielded to capture sparse resistance
mutations and do not incorporate mutation hotspots, ensuring that
even multi-resistant M. tuberculosis isolates are characterized as M.
tuberculosis. Analysis of these amplicon base compositions from
our isolate indicated the presence of a NTM in the sample.
The second assay was the MDR-TB assay, designed to target
genes known to harbour drug resistance mutations. It can also
identify and differentiate NTM using the same drug resistance loci.
The capture of a resistance mutation typically yields a base
composition that is only a 1-SNP (single nucleotide polymorphism)
variant of the base composition expected for M. tuberculosis. In
contrast, multiple changes in distinct primer pairs can accumulate
for NTM species (e.g. for primer pair 4237: [A16 G29 C23 T18] for
M. tuberculosis, [A16 G25 C27 T18] for Mycobacterium intracellu-
lare). Combining multiple amplicons yields composite, increasing-
ly distinct signatures that are unequivocally associated with either
resistant M. tuberculosis or a given NTM species. The signature of
our isolate had a clean, full match (6/6) to the M. sherrisii ATCC
BAA-832 strain. It was also clearly distinguished from another
200+ NTM species that are represented in the current database.
This is to our knowledge, the ﬁrst utilization of a PCR/ESI-MS
system to assist in the management of a mycobacterial infection.
PCR/ESI-MS differs from whole genome sequencing by not
covering the entire gene for each target. Both methods have the
ability to provide high throughput deﬁnitive identiﬁcation that
could supersede traditional sequencing methods.
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